TDTyler C. Dunlap

Tyler C. Dunlap

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tyler C. Dunlap has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Evaluation and Extrapolation of a Tacrolimus Population Pharmacokinetic Model in Adult Recipients of Allogeneic Hematopoietic Cell Transplantation Receiving Post‐Transplant Cyclophosphamide

    by Riley M. Randolph, Tyler C. Dunlap, Stephany Gonzalez Tineo, Ryan M. Kemper, Jing Zhu, Kieran Collins, Yu Fei Wang, Pu Ouyang, Nichole Korpi‐Steiner, Eric Weimer, et al.

    Allogeneic hematopoietic cell transplant (allo‐HCT) is potentially curative for many hematologic diseases but complicated by acute graft‐versus‐host disease (aGVHD). While tacrolimus remains the cornerstone of aGVHD prophylaxis, regimens are increasingly including post‐transplant cyclophosphamide (PTCy). This single‐center study evaluated a previously published tacrolimus population pharmacokinetic (popPK) model developed from allo‐HCT recipients administered standard (tacrolimus plus methotrexate) aGVHD prophylaxis for generalizability to PTCy recipients. Adult allo‐HCT recipients treated with PTCy for aGVHD prophylaxis were included. Applicability of the established popPK model to the PTCy population was based on an evaluation of simulated to observed concentration ratios, and the distribution was interpreted with respect to a clinical equivalence range (0.8 to 1.25). The model was refit using data from both the standard and PTCy cohorts to describe the PK and support extrapolation to the PTCy population. Individual PK parameters from PTCy recipients were used to simulate steady‐state concentrations (C trough, ss ) using the current institutional weight‐based dosing strategy and the proposed model‐informed precision dosing (MIPD) algorithm. The proportion of patients predicted to experience a subtherapeutic C trough, ss (trough, ss values from 95 allo‐HCT recipients who received PTCy were included. The previous model did not successfully predict tacrolimus C trough, ss values among PTCy patients, but highlighted similarities between clearance in PTCy and standard aGVHD prophylaxis patients who received reduced‐intensity conditioning. Dosing simulations suggested a decreased proportion of PTCy patients would experience subtherapeutic tacrolimus C trough, ss with MIPD (3%) compared to conventional weight‐based dosing (23%).

  • Evaluating Day +90 Donor Chimerism as a Prognostic Marker of Clinical Outcomes Among Allogeneic Hematopoietic Cell Transplant Recipients Who Received Myeloablative Conditioning

    by Sara Jubas, Kieran Collins, Kendall Obara, Hsuan-Hui (Grace) Liu, Ryan M. Kemper, Alexandra L.W. Kelley, Arushi Goel, Tyler C. Dunlap, Jing Zhu, Riley M. Randolph, et al.

  • Antibody Transfer From Mother to Fetus/Infant: An Opportunity for Model‐Informed Precision Medicine

    by Miramar Sami Kardouh, Tyler Dunlap, Rui Zhong, Jacqueline B. Tiley, Yanguang Cao

  • A Tacrolimus Population Pharmacokinetic Model for Adult Allogeneic Hematopoietic Cell Transplant Recipients Provides Clinical Opportunities for Precision Dosing

    by Tyler C. Dunlap, Jing Zhu, Daniel L. Weiner, Ryan M. Kemper, Susanna C. DeVane, Feiyun Ma, Veronica Nguyen, James M. Coghill, Viet Dang, Tatjana Grgic, et al.

    Background Tacrolimus is a cornerstone of acute graft-versus-host disease (aGVHD) prophylaxis in allogeneic hematopoietic cell transplant (allo-HCT) recipients. However, a narrow therapeutic index and high interindividual variability in pharmacokinetics (PK) make starting dose selection a major challenge in clinical practice. Methods Data from two PK studies conducted at the University of North Carolina Medical Center (UNCMC) were used to develop an oral tacrolimus population pharmacokinetic (popPK) model specific to adult allo-HCT recipients. Monte Carlo simulations were performed to compare the likelihood of achieving the UNCMC institutional target trough concentration range (ITR) (5–10 ng/mL) on the day of transplant (D0) under the current institutional dosing protocol, dosing recommendations from the Clinical Pharmacogenetics Implementation Consortium (CPIC), and model-derived dosing recommendations. Results In total, 290 allo-HCT recipients contributed a total of 906 PK samples to the final analysis. A two-compartment popPK model adequately described the PK data. Population typical values of apparent clearance (TVCL/F) for 70 kg individuals receiving reduced intensity conditioning were 0.33 L/h/kg for CYP3A5 poor metabolizers (PMs) and 0.70 L/h/kg for intermediate and normal metabolizers (IMs and NMs). The probability of the population-level average D0 trough concentration being within the UNCMC ITR under the current UNCMC weight-based dosing protocol, CPIC-based, and model-derived dosing strategies were estimated to be 37%, 45%, and 76%, respectively. CYP3A5 IMs and NMs were predicted to require a 100% dose increase relative to CYP3A5 PMs. Conclusions We propose a new oral tacrolimus dosing strategy for adult allo-HCT recipients, which suggests the current weight-based dosing paradigm is insufficient. This new strategy includes CYP3A5 metabolizer phenotypes and conditioning regimen intensity, and could increase the percentage of allo-HCT recipients achieving target concentrations on D0. Clinical Trial Registration Number Clinicaltrials.gov NCT04645667


  • Optimizing Maternal and Fetal Antibody Exposure and Dosing Regimens During Pregnancy Using a Physiologically Based Pharmacokinetic Model

    by Miramar Sami Kardouh, Tyler C. Dunlap, Rui Zhong, Jacqueline B. Tiley, Yanguang Cao

    Therapeutic antibodies are often prescribed off‐label to pregnant patients to treat inflammatory, autoimmune, or malignant conditions. Despite their broad use, the extent of fetal exposure to such therapeutic antibodies and the risk to fetal development remain largely unknown. Given the ethical challenges to conduct randomized trials in pregnant patients, modeling and simulation approaches offer an opportunity to yield mechanistic insights using data from observational studies. In this study, a physiologically based pharmacokinetic (PBPK) modeling framework was developed to predict maternal and fetal therapeutic antibody exposures throughout pregnancy. The model incorporates expression data on the placental neonatal Fc receptor (FcRn), a receptor critical to transplacental IgG transfer. FcRn‐mediated transplacental antibody transfer was described by three endosomal compartments: (1) maternal vascular endothelial cells; (2) syncytiotrophoblast cells; and (3) fetal vascular endothelial cells. The model was calibrated and validated using endogenous IgG concentrations and pharmacokinetic data from > 2,000 non‐pregnant subjects, 167 pregnant women, and 268 infants. Overall, the minimal PBPK model adequately captured the observations, with predictions falling within a twofold range of maternal and fetal concentrations as follows: infliximab (54% and 50%), adalimumab (100% and 70%), ustekinumab (38% and 41%), vedolizumab (92% and 77%), and etanercept (75% and 33%). In addition, the PBPK framework supported the evaluation of infliximab and adalimumab dosing regimens that maintain maternal therapeutic levels while minimizing fetal exposure. This study provides a generalizable PBPK framework including FcRn ontogeny, implemented in a user‐friendly tool, to predict transplacental transfer of many biologics and to support appropriate dosing regimens throughout pregnancy.


  • Evaluation of Obesity‐Related Physiological Changes on Pantoprazole Clearance in Children Using a Population Pharmacokinetic Approach

    by Tyler C. Dunlap, Daniel Gonzalez, Kathryn E. Kyler, Victória Etges Helfer, Veronica Williams, Chance S. Friesen, Nathan Artz, Sherwin Chan, Valentina Shakhnovich

    Pediatric obesity is a growing health concern, affecting millions of children worldwide. While pharmacokinetic (PK) changes in numerous commonly prescribed medications have been linked to obesity, the physiological mechanisms driving these alterations and their implications for drug dosing remain poorly understood. The objective of this study was to evaluate previously reported observations of reduced pantoprazole clearance (CL) in children with obesity, investigate obesity‐related characteristics in liver physiology as explanatory causes for these observations, and evaluate the clinical relevance of obesity on drug dosing. A prospective, comparative PK study, enrolling participants 6‐21 years of age, with and without obesity, was conducted to evaluate the association between obesity‐related characteristics and pantoprazole CL. A nonlinear mixed‐effects modeling approach was used to identify sources of interindividual variability in pantoprazole PK. Monte Carlo simulations were performed to assess pantoprazole exposure in children and evaluate the association between obesity and pantoprazole exposure. The study population consisted of 39 pediatric participants: 31% without obesity and 69% with obesity. A two‐compartment PK model with covariate effects of total body weight (TBW), CYP2C19 metabolizer phenotype, and obesity status adequately described the PK data. After accounting for differences due to TBW and CYP2C19 metabolizer phenotype, obesity was associated with an estimated 18% reduction in pantoprazole CL (comparable to the reduction estimated for a CYP2C19 loss of function allele). Further research is warranted to evaluate the physiological mechanisms associated with reduced drug CL in children with increased body size and the implications for drug dosing.


  • Utilization of a Population Pharmacokinetic Model to Improve a Busulfan Test‐Dose Strategy in Allogeneic Hematopoietic Cell Transplant Recipients

    by Tyler C. Dunlap, Daniel L. Weiner, Ryan M. Kemper, Miramar Kardouh, Susanna C. DeVane, Allison Symonds, J. Ryan Shaw, Paul M. Armistead, Jonathan R. Ptachcinski, Daniel J. Crona

    Busulfan is an alkylating agent used as part of conditioning chemotherapy regimens prior to allogeneic hematopoietic cell transplant (allo-HCT). Pharmacokinetic (PK)-guided test-dose strategies have been shown to improve the number of patients achieving busulfan exposure goals and improve clinical outcomes. However, current practices require extensive PK sampling. In this study, PK data were retrospectively collected from busulfan drug monitoring records from adult allo-HCT recipients who received once-daily intravenous busulfan at the University of North Carolina Medical Center (UNCMC). A population pharmacokinetic (popPK) model was developed to identify sources of interindividual variability and evaluate alternative PK sampling strategies. A 2-compartment model, with covariate effects of actual body weight and sex, best described the data. The typical value of clearance for an 83 kg male was estimated to be 11.21 L/h. Fifty-nine percent of allo-HCT recipients were estimated to have met the UNCMC institutional myeloablative conditioning (MAC) exposure goal based on model post hoc estimates of clearance using all PK samples obtained following MAC dosing. Fifty-seven percent of patients were estimated to have met this goal based on post hoc estimates using a single PK sample. Our results indicate once-daily, intravenous busulfan PK in adult allo-HCT recipients receiving MAC dosing can be reasonably described by a popPK model, and the use of a sparse PK sampling strategy may be feasible for determining target exposure attainment following MAC dosing. Use of a popPK model and sparse PK sampling strategy to carry out busulfan test-dose procedures could reduce health care costs and inconvenience to patients.


  • Open Access

    Population Dynamics of Immunological Synapse Formation Induced by Bispecific T-cell Engagers Predict Clinical Pharmacodynamics and Treatment Resistance

    by Can Liu, Jiawei Zhou, Stephan Kudlacek, Timothy Qi, Tyler Dunlap, Yanguang Cao

    Effector T cells form immunological synapses (IS) with recognized target cells to elicit cytolytic effects. Facilitating IS formation is the principal pharmacological action of most T cell-based cancer immunotherapies. However, the dynamics of IS formation at the cell population level, the primary driver of the pharmacodynamics of many cancer immunotherapies, remains poorly defined. With classic immunotherapy CD3/CD19 bispecific T cell engager (BiTE) as a model system, we integrate experimental and theoretical approaches to investigate the population dynamics of IS formation and their relevance to clinical pharmacodynamics and treatment resistance. Our models produce experimentally consistent predictions when defining IS formation as a series of spatiotemporally coordinated events driven by molecular and cellular interactions. The models predict tumor-killing pharmacodynamics in patients and reveal trajectories of tumor evolution across anatomical sites under BiTE immunotherapy. Our model highlight the bone marrow may serve as a sanctuary site permitting tumor evolution and antigen escape. The models also suggest the optimal dosing regimens as a function of tumor growth and patient T cell abundance that confer adequate tumor control with minimal disease evolution. This work has implications for developing more effective T cell-based cancer immunotherapies.